MAPT and Alzheimer disease: Myricetin and epicatechin-5-gallate have been shown to suppress heparin-induced tau production and administration of EGCG leads to regulated tau profiles in AD transgenic mouse model, with inhibition of sarkosyl-soluble phosphorylated tau isoforms [39,40].